Pfizer's Xeljanz (tofacitinib) Receives the US FDA's Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis
{"Image Orientation": "Horizontal (normal)", "Image XResolution": "96", "Image YResolution": "96", "Image ResolutionUnit": "Pixels/Inch", "Image ExifOffset": "90", "EXIF ExifImageWidth": "752", "EXIF ExifImageLength": "440"}